Thus, the 2 agents potentially provide a theranostic approach for selecting and treating patients with CAIX-expressing tumors such as ccRCC, CRC, and pancreatic ductal adenocarcinoma. This evidence concerns the gene CA9 and pancreatic ductal adenocarcinoma.